Download PDF
Aktuelle Dermatologie 2004; 30(1/02): 30-35
DOI: 10.1055/s-2004-814281
Originalarbeit
© Georg Thieme Verlag Stuttgart · New York

Aktuelle Aspekte der Lepra-Therapie

Current Aspects of Leprosy TherapyC.  Bendick1
  • 1 University of Health Sciences, Department of Dermatology, Phnom Penh, Kambodscha
Further Information

Publication History

Publication Date:
03 March 2004 (online)

Also available at
   Permissions and Reprints

Zusammenfassung

Die medikamentöse Therapie der Lepra hat in den letzten Jahrzehnten erhebliche Fortschritte gemacht. Vor dem Hintergrund der weltweiten Bemühungen um die Elimination der Erkrankung werden historische, gegenwärtige sowie neue und experimentelle Therapiestrategien erörtert und kritisch gewürdigt. Bedingungen für den künftigen Einsatz therapeutischer Regime sowie wesentliche Herausforderungen im Hinblick auf die medikamentöse Therapie der Lepra werden aufgezeigt.

Abstract

Drug therapy of leprosy has made great advances in the past decades. Regarding the worldwide efforts towards the elimination of the disease, historical, current and new, as well as experimental therapeutic strategies, are discussed and critically assessed. Conditions for the future application of therapeutic regimens, and essential challenges concerning the drug therapy of leprosy are elaborated.

Literatur

  • 1 World Health Assembly . Leprosy resolution 44.9. Forty-fourth World Health Assembly 13. 5. 1991
    Google Scholar
  • 2 World Health Assembly .Press release World Health Assembly 54/2,. 16. 5. 2001
    Google Scholar
  • 3 World Health Organization .The final push strategy to eliminate leprosy as a public health problem. Questions and answers. 2.Aufl. Genf; World Health Organization 2003
    Google Scholar
  • 4 Lockwood D N. Leprosy elimination - a virtual phenomenon or a reality?.  Brit Med J. 2002;  324 (7352) 1516-1518
    PubMedGoogle Scholar
  • 5 Stearns A T. Leprosy: a problem solved by 2000.  Lepr Rev. 2002;  73 (3) 215-224
    PubMedGoogle Scholar
  • 6 Feenstra P. „Elimination” of leprosy and the need to sustain leprosy services, expectations, predictions and reality.  Int J Lepr Other Mycobact Dis. 2003;  71 (3) 248-256
    CrossrefPubMedGoogle Scholar
  • 7 Yawalkar S J. Leprosy for Medical Practitioners and Paramedical Workers. 7. Auflage. Basel; Novartis Stiftung 2002
    Google Scholar
  • 8 Faget G H, Pogge R C, Johansen F A, Dinan J F, Prejean B M, Eccles C G. The promin treatment of leprosy - a progress report.  Pub Health Rep. 1943;  58 1729-1741
    PubMedGoogle Scholar
  • 9 Fromm E, Wittmann J. Derivate des p-Nitrophenols.  Berichte Deutsch Chem Ges. 1908;  41 2264-2273
    PubMedGoogle Scholar
  • 10 Cochrane R, Ramanujam H, Paul H. et al . Two-and-a-half years experimental work on the sulphone group of drugs.  Lepr Rev. 1949;  20 4-64
    PubMedGoogle Scholar
  • 11 Lowe J. The late results of sulphone treatment of leprosy in East Nigeria.  Lepr Rev. 1954;  25 (3) 13-124
    PubMedGoogle Scholar
  • 12 Pettit J HS, Rees R JW. Sulphone resistance in leprosy. An experimental and clinical study.  Lancet. 1964;  II 673-674
    PubMedGoogle Scholar
  • 13 Pearson J MH, Haile G S, Rees R JW. Primary dapsone-resistant leprosy.  Lepr Rev. 1977;  48 (2) 129-132
    PubMedGoogle Scholar
  • 14 WHO-Study Group .Chemotherapy of leprosy for control programmes. Tech Rep Ser 675. Genf; World Health Organization 1982
    Google Scholar
  • 15 World Health Organization .Guide to Eliminate Leprosy as a Public Health Problem. WHO/CDS/CPE/CEE/2000.14. Genf; World Health Organization 2000
    Google Scholar
  • 16 Georgiev G D, McDougall A C. Blister calendar packs - potential for the improvement in supply and utilization of multiple drug therapy in leprosy control programmes.  Int J Lepr. 1988;  56 (4) 603-610
    PubMedGoogle Scholar
  • 17 Huikeshoven H. Patient compliance in leprosy control: a necessity in old and new regimens.  Int J Lepr. 1985;  53 (3) 474-480
    PubMedGoogle Scholar
  • 18 Ridley D S, Jopling W H. Classification of leprosy according to immunity. A five-group system.  Int J Lepr Other Mycobact Dis. 1966;  34 (3) 255-273
    PubMedGoogle Scholar
  • 19 WHO Expert Committee on Leprosy .6th Report. Tech Rep Ser 768. Genf; World Health Organization 1988
    Google Scholar
  • 20 Goulart I M, Arbex G L, Carneiro M H, Rodrigues M S, Gadia R. [Adverse effects of multidrug therapy in leprosy patients: a five-year survey at a Health Center of the Federal University of Uberlandia].  Rec Soc Bras Med Trop. 2002;  35 (5) 453-460 (portugiesisch)
    PubMedGoogle Scholar
  • 21  . Editorial. Adverse reactions to dapsone.  Lancet. 1981;  II 184-185
    PubMedGoogle Scholar
  • 22 Rees R JW, Pearson J MH, Waters M FR. Experimental and clinical studies of rifampicin in treatment of leprosy.  Brit Med J. 1970;  1 89-x
    PubMedGoogle Scholar
  • 23 Leiker D L, Kamp H. First results of treatment of leprosy with Rifadin.  Lepr Rev. 1970;  41 (1) 25-30
    PubMedGoogle Scholar
  • 24 Languillon J, Yawalkar S J, McDougall A C. Therapeutic effect of adding rimactane (rifampicin) 450 milligrams daily or 1200 milligrams once monthly in a single dose to dapsone 50 milligrams daily in patients with lepromatous leprosy.  Int J Lepr. 1979;  47 (1) 37-43
    PubMedGoogle Scholar
  • 25 Browne S G, Hogerzeil L M. „B 663” in the treatment of leprosy. Preliminary report of a pilot trial.  Lepr Rev. 1962;  33 6-10
    PubMedGoogle Scholar
  • 26 Waters M FR. G 30 320 or B 663 - Lampren (Geigy).  Lepr Rev. 1969;  40 (1) 21-47
    PubMedGoogle Scholar
  • 27 Zimmerli-Ning M, Vischer W. A retrospective survey of the tolerability of clofazimine in patients with bacilliferous leprosy. Abstract III/137(A). New Delhi; XII. International Leprosy Congress 1984
    Google Scholar
  • 28 Jacobson R R, Hastings R C. Rifampicin resistant leprosy.  Lancet. 1976;  II 1304-1305
    PubMedGoogle Scholar
  • 29 Grosset J H, Guelpa-Lauras C C, Bobin P, Brucker G, Cartel J L, Constant-Desportes M, Flageul B, Frederic M, Guillaume J C, Millan J. Study of 39 documented relapses of multibacillary leprosy after treatment with rifampicin.  Int J Lepr. 1989;  57 (3) 607-614
    PubMedGoogle Scholar
  • 30 WHO Study Group .Chemotherapy of leprosy. Tech Rep Ser 874. Genf; World Health Organization 1998
    Google Scholar
  • 31 Yoder L J, Jacobson R R, Hastings R C. The activity of rifabutin against Mycobacterium leprae.  Lepr Rev. 1991;  62 (3) 280-287
    PubMedGoogle Scholar
  • 32 Ji B, Grosset J. Combination of rifapentine-moxifloxacin-minocycline (PMM) for the treatment of leprosy.  Lepr Rev. 2000;  71 (Suppl.) S81-S87
    PubMedGoogle Scholar
  • 33 Grosset J H. Newer drugs in leprosy.  Int J Lepr Other Mycobakt Dis. 2001;  69 (Suppl.) S14-S18
    PubMedGoogle Scholar
  • 34 Gelber R H. Successful treatment of a lepromatous patient with clarithromycin.  Int J Lepr Other Mycobact Dis. 1995;  63 (1) 113-115
    PubMedGoogle Scholar
  • 35 Ji B, Jamet P, Perani E G, Sow S, Lienhardt C, Petinon C, Grosset J H. Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients.  Antimicrob Agents Chemother. 1996;  40 (9) 2137-2141
    PubMedGoogle Scholar
  • 36 Ji B, Grosset J H. Ofloxacin for the treatment of leprosy.  Acta Lepr. 1991;  7 (4) 321-326
    PubMedGoogle Scholar
  • 37 Consigny S, Bentoucha A, Bonnafous P, Grosset J, Ji B. Bactericidal activities of HMR 3647, moxifloxacin and rifapentine against Mycobakterium leprae in mice.  Antimicrob Agents Chemother. 2000;  44 (10) 2919-2921
    CrossrefPubMedGoogle Scholar
  • 38 Nakashima M, Uematsu T, Kanamaru M, Okazaki O, Hakusui H. Phase I study of levofloxacin,(s)-(-)-ofloxacin.  Jpn J Clin Pharmacol Ther. 1992;  23 515-521
    PubMedGoogle Scholar
  • 39 Dhople A M, Namba K. In vivo susceptibility of Mycobacterium leprae to sitafloxacin (DU-6859a), either singly or in combination with rifampicin analogues.  Int J Antimicrob Agents. 2003;  21 (3) 251-255
    PubMedGoogle Scholar
  • 40 Bharti R. Pefloxacin in leprosy.  Indian J Lepr. 1994;  66 (4) 443-448
    PubMedGoogle Scholar
  • 41 Chan G P, Garcia-Ignacio B Y, Chavez V E, Livelo J B, Jimenez C L, Parrilla M L, Franzblau S G. Clinical trial of sparfloxacin for lepromatous leprosy.  Antimicrob Agents Chemother. 1994;  38 (1) 61-65
    PubMedGoogle Scholar
  • 42 Gelber R H, Fukuda K, Byrd S, Murray L P, Siu P, Tsang M, Rea T H. A clinical trial of minocycline in lepromatous leprosy.  Brit Med J. 1992;  304 (6819) 91-92
    PubMedGoogle Scholar
  • 43 WHO Expert Committee on Leprosy .7th Report. Tech Rep Ser 874. Genf; World Health Organization 1998
    Google Scholar
  • 44 Single-Lesion Multicentre Trial Group . Efficacy of single dose multidrug therapy for treatment of single-lesion paucibacillary leprosy.  Indian J Lepr. 1997;  69 (2) 121-129
    PubMedGoogle Scholar
  • 45 Gupta M D. Field trials with a single dose of the combination rifampicin-ofloxacin-minocycline (ROM) for the treatment of paucibacillary leprosy.  Lepr Rev. 2000;  71 (Suppl.) S77-S80
    PubMedGoogle Scholar
  • 46 Ustianowski A P, Lockwood D NJ. Leprosy: current diagnostic and treatment approaches.  Curr Opin Inf Dis. 2003;  16 (5) 421-427
    PubMedGoogle Scholar
  • 47 Daumerie D. Current World Health Organization sponsored studies in the chemotherapy of leprosy.  Lepr Rev. 2000;  71 (Suppl.) S88-S90
    PubMedGoogle Scholar
  • 48 WHO-Study Group .Chemotherapy of leprosy for control programmes. Tech Rep Ser 675. Genf; World Health Organization 1982
    Google Scholar
  • 49 WHO study group .Chemotherapy of leprosy. Report of a WHO study group. Tech Rep Ser 847. Genf; World Health Organization 1994
    Google Scholar
  • 50 WHO Expert Committee on leprosy .Tech Rep Ser 874. Genf; World Health Organization 1998
    Google Scholar
  • 51 Technical Advisory Group on elimination of leprosy .Report on third meeting of the WHO Conclusions and recommendations. Report No. WHO/CDS/CPE/CEE 2002.29. Genf; World Health Organization 2002
    Google Scholar
  • 52 Ji B, Saunderson P. Uniform MDT (U-MDT) regimen for all leprosy patients: another example of wishful thinking.  Lepr Rev. 2003;  74 (1) 2-6
    PubMedGoogle Scholar
  • 53 World Health Organization .Guide to Eliminate Leprosy as a Public Health Problem. WHO/CDS/CPE/CEE/2000.14. Genf; World Health Organization 2000
    Google Scholar
  • 54 Ji B. Accompanied MDT (AMDT) - more questions than answers.  Lepr Rev. 2002;  73 (4) 301-307
    PubMedGoogle Scholar
  • 55 Jacobson R R. Needed research in chemotherapy of leprosy related to the individual patient.  Int J Lepr Other Mycobact Dis. 1996;  64 (Suppl.) S16-S20
    PubMedGoogle Scholar
  • 56 Curtiss R 3rd, Blower S, Cooper K, Russell D, Silverstein S, Young L. Leprosy research in the post-genome era.  Lepr Rev. 2001;  72 (1) 8-22
    PubMedGoogle Scholar
  • 57 Ridley D S. Bacterial indices. In: Cochrane RG, Davey TF (Hrsg.) Leprosy in theory and practice. Bristol; 1964
    Google Scholar

1 Exazerbationen des ansonsten hoch chronischen Krankheitsverlaufes der Lepra werden als Reaktionen bezeichnet. Man unterscheidet die Typ I-Reaktion, welche durch einen - oftmals therapieinduzierten - Anstieg der zellvermittelten Immunität verursacht wird, von der Typ II-Reaktion (Erythema nodosum leprosum [ENL]), die man als ein durch Präzipitation von Ag/Ak-Komplexen verursachtes Immunkomplex-Syndrom auffasst. Typ I-Reaktionen kommen bei BT, BB- und BL-, selten auch bei TT-Fällen vor, Typ II-Reaktionen sind in aller Regel auf LL-, gelegentlich auch BL-Fälle beschränkt.

Dr. Christoph Bendick

Gotenring 33 · 50679 Köln

Email: soksabay@yahoo.com